APLS250117C135000
- 0.05
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Stifel Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
TD Cowen Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $60
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Buy Rating Maintained for Apellis Pharmaceuticals: Strategic Market Position and Growth Potential Justify Price Objective
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Goldman Sachs Downgrades Apellis Pharmaceuticals to Neutral From Buy, $36 Price Target
Apellis Pharmaceuticals Price Target Announced at $36.00/Share by Goldman Sachs
Apellis Pharmaceuticals Analyst Ratings
Goldman Sachs Downgrades Apellis Pharmaceuticals(APLS.US) to Hold Rating
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Buy Rating for Apellis Pharmaceuticals: Promising Growth Potential of Syfovre in Geographic Atrophy Market
RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Initiated at Equal-Weight by Morgan Stanley
Apellis Pharmaceuticals Analyst Ratings
Morgan Stanley Initiates Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $31
Neutral Stance on Apellis Pharmaceuticals Amid Competitive Uncertainties and Market Stability
Scotiabank Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57